CME rebuts accusations of procyclical margining

Merc issues white paper touting strong portfolio-level coverage during pandemic, rebuffs calls for higher MPOR

CME

CME Clearing has sought to rebut complaints that its margins were too low in the advent of the coronavirus pandemic last year, and that demands subsequently rose too rapidly as Covid-19’s spread caused a sustained spike in market volatility.

In a soon-to-be-released white paper seen by Risk.net, CME analyses its own performance during the Covid-19 pandemic, offering evidence to support its long-standing argument that its existing anti-procyclicality mechanisms are enough to help dampen margin

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: